FOLH1 and prostate cancer: The ligand of 177Lu-PSMA617 anchors on prostate specific membrane antigen (PSMA), which is a type II transmembrane protein that expressed highly on most prostate cancer cells but absent on most normal tissues (Afshar-Oromieh et al., 2016).